BRAF and melanoma: Inhibition of the BRAF oncoprotein by vemurafenib has been shown to be highly effective in BRAFV600E melanoma patients [22]; in contrast, the same treatment has limited effect on BRAFV600E colon cancer patients due to intrinsic resistance against BRAF inhibitors [6,23].